- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00304655
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This study was designed to prove safety and efficacy of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder in Korea and to confirm the maintenance of efficacy and safety during maintenance period and the changes in emotional factors and social functions.
After administering 15 mg/day of aripiprazole for two weeks, the test may change the dose within the range of 10 mg and 30 mg per day by clinical judgment. (Medication duration: 8 weeks (acute phase) + 18 weeks (maintenance phase)] + 26 weeks (extension phase), *total 52 weeks)
Studietype
Inschrijving
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
-
Seoul, Korea, republiek van, 110-744
- Seoul National University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Schizophrenia or schizoaffective disorder patients as defined by the DSM-IV criteria having an acute relapse
- 18 to 65 years
- Males and females (females of child bearing potential must use acceptable contraception and must not be pregnant and lactating; females of child-bearing potential must have negative serum pregnancy test)
- Randomization to this study must occur no more than four weeks following the day of initiation of treatment for the present episode/relapse.
- Should have a total PANSS score of at least 60. In addition, patients should have scores of at least 4 ("moderate") on any two of the four PANSS items that constitute the psychotic item subscale (hallucinatory behavior, delusions, conceptual disorganization, and suspiciousness).
- Patients must be able to be rated reliably on the battery of psychiatric and movement rating scales required by the protocol.
- Patients eligible to enter the study must sign an informed consent form.
Exclusion Criteria:
- Patients who are violent
- Patients who, in the opinion of the investigator, have serious suicidal ideation
- Patients who are liable to serious suicide attempt, by clinical judgment
- Patients who currently have a psychiatric diagnosis other than schizophrenia, schizophrenic form disorder or schizoaffective disorder requiring pharmacotherapy
- Patients who have any of the following neurologic diagnoses: migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, residual of stroke, transient cerebral ischemic attacks, "cerebral palsy" or any other condition that requires intermittent or maintenance treatment, or which is manifested by any abnormality on neurologic examination
- Patients who must continue to take, or who may potentially need to take, during this study, any of the following concomitant medication, which could cause unwanted drug-to-drug interactions or which could confound the analysis of antipsychotic effectiveness: Tegretol (carbamazepine), Depakene Depakote (valproic acid or sodium valproate or divalproate sodium), Lithium carbonate and lithium citrate
- Patients under treatment of schizophrenia : those who had taken antipsychotic drugs (consta) before randomization
- Patients who must continue to take, during this study, drugs or substances known as strong suppressive agents of microsomal enzyme CYP2D6
- Patients with any gastrointestinal resection, stomach stapling, or any other condition that may impair the absorption of the study medication
- Patients who currently meet the DSM-IV criteria for psychoactive substance dependence or patients with a history of substance or alcohol dependence (according to the DSM-IV criteria) within one month prior to the beginning of the study
- Patients having any somatic condition whose symptoms or physical signs could be misinterpreted as signs or symptoms of psychosis or as adverse effects from antipsychotic medications.
- Patients with any acute or unstable medical condition requiring pharmacotherapy
- Patients with any abnormal laboratory test result as judged by investigator
- Patients who have participated in any previous aripiprazole clinical study
- Patients having taken an investigational drug within the four weeks which precede the start of placebo washout
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
PANSS-total score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
Secundaire uitkomstmaten
Uitkomstmaat |
---|
[Efficacy] PANSS-positive, PANSS-negative, CGI-severity score (at screening, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
[Safety] AEs (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
SAS, AIMS, Barnes (at baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
vital signs (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
body weight (at screening, baseline, week 1, 2, 3, 4, 6, 8, 12, 16, 26, 40, 52)
|
electrocardiogram (ECG) (at screening & week 8)
|
serum prolactin concentration (at screening & week 8)
|
routine laboratory test (at screening & week 8)
|
urinalysis (at screening & week 8)
|
Pharmacokinetic is evaluated by concentration of aripiprazole in blood (at Week 3, 4, 6, 8).
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Jun-Su Kwon, Prof., Seoul National University Hospital
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Psychische aandoening
- Schizofreniespectrum en andere psychotische stoornissen
- Schizofrenie
- Psychotische stoornissen
- Fysiologische effecten van medicijnen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Depressiva van het centrale zenuwstelsel
- Antipsychotica
- Rustgevende agenten
- Psychotrope medicijnen
- Serotonine agenten
- Antidepressiva
- Dopamine-agonisten
- Dopamine-agenten
- Serotonine 5-HT1-receptoragonisten
- Serotoninereceptoragonisten
- Serotonine 5-HT2-receptorantagonisten
- Serotonine-antagonisten
- Dopamine D2-receptorantagonisten
- Dopamine-antagonisten
- Aripiprazol
Andere studie-ID-nummers
- KOP-010401
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Aripiprazol
-
Otsuka Beijing Research InstituteVoltooid
-
National Institute on Alcohol Abuse and Alcoholism...Brown UniversityVoltooidAlcohol afhankelijkheidVerenigde Staten
-
Otsuka Pharmaceutical Co., Ltd.VoltooidErnstige depressieve stoornisJapan
-
University of California, Los AngelesAlkermes, Inc.BeëindigdSchizofrenie | Schizofreniforme stoornis | Schizoaffectieve stoornis, depressief typeVerenigde Staten
-
Veterans Medical Research FoundationBristol-Myers SquibbVoltooid
-
Otsuka Pharmaceutical Co., Ltd.Voltooid
-
H. Lundbeck A/SOtsuka Pharmaceutical Co., Ltd.VoltooidSchizofrenieVerenigde Staten
-
Otsuka Pharmaceutical Development & Commercialization...VoltooidSchizofrenieKorea, republiek van, Verenigde Staten, Estland, Italië, Hongarije, Bulgarije, Kroatië, Frankrijk, Polen, Thailand, Puerto Rico, Chili, Zuid-Afrika, Oostenrijk, België
-
Alkermes, Inc.VoltooidSchizofrenieVerenigde Staten
-
Alkermes, Inc.VoltooidSchizofrenieVerenigde Staten